Ionis Pharmaceuticals (IONS) stock price, revenue, and financials

Ionis Pharmaceuticals market cap is $8.3 b, and annual revenue was $599.67 m in FY 2018

$8.3 B

IONS Mkt cap, 27-Jan-2020

$167.9 M

Ionis Pharmaceuticals Revenue Q3, 2019
Ionis Pharmaceuticals Gross profit (Q3, 2019)166.9 M
Ionis Pharmaceuticals Gross profit margin (Q3, 2019), %99.4%
Ionis Pharmaceuticals Net income (Q3, 2019)26.2 M
Ionis Pharmaceuticals EBIT (Q3, 2019)2.5 M
Ionis Pharmaceuticals Cash, 30-Sept-2019247.9 M
Ionis Pharmaceuticals EV8.7 B

Ionis Pharmaceuticals Income Statement

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

23.5m28.6m21.1m24.8m20.7m23.2m47.3m11.6m43.4m38.1m23.6m28.2m57.1m44.1m62.6m120.4m49.1m36.9m38.5m110.9m110.3m104.2m120.9m144.4m117.7m145.4m297.2m163.8m167.9m

Cost of goods sold

1.0m1.4m967.0k

Gross profit

296.2m162.4m166.9m

Gross profit Margin, %

100%99%99%

R&D expense

39.1m34.7m34.2m36.0m39.9m38.7m40.4m36.6m38.3m42.6m

General and administrative expense

3.1m2.9m3.0m2.9m3.1m3.0m3.2m3.1m3.4m3.4m3.4m4.4m4.5m4.5m7.5m7.8m8.8m10.6m9.8m10.2m13.7m22.3m26.8m43.7m66.2m68.7m68.2m75.1m60.0m

Operating expense total

42.2m37.6m37.3m38.9m43.0m41.7m43.6m39.6m41.7m46.0m3.4m4.4m4.5m4.5m7.5m7.8m8.8m10.6m9.8m10.2m13.7m22.3m26.8m43.7m66.2m68.7m174.6m181.3m164.4m

EBIT

(18.7m)(8.9m)(16.1m)(14.1m)(22.3m)(18.5m)3.7m(28.0m)1.6m(7.9m)(25.5m)(29.7m)(6.6m)(21.5m)(9.3m)44.6m(48.1m)(54.7m)(48.9m)16.1m14.0m(1.7m)13.9m(3.3m)(50.3m)(18.6m)121.5m(18.8m)2.5m

EBIT margin, %

(79%)(31%)(76%)(57%)(108%)(79%)8%(242%)4%(21%)(108%)(105%)(12%)(49%)(15%)37%(98%)(148%)(127%)15%13%(2%)12%(2%)(43%)(13%)41%(11%)2%

Interest expense

3.3m3.3m3.4m3.4m4.8m5.2m5.2m5.9m4.8m4.8m

Investment income

859.0k776.0k705.0k616.0k575.0k600.0k477.0k408.0k376.0k589.0k434.0k657.0k671.0k675.0k845.0k917.0k1.2m1.5m1.5m989.0k2.3m2.5m2.8m3.6m5.1m10.0m12.1m13.7m13.1m

Pre tax profit

(26.9m)(24.0m)(1.2m)(38.3m)(1.7m)(11.3m)(29.8m)(33.6m)(11.2m)(25.3m)(17.5m)36.4m(35.8m)(62.7m)(57.1m)7.4m3.5m(11.0m)(3.9m)(10.8m)(56.2m)(19.9m)121.9m(16.9m)3.5m

Income tax expense

2.0k9.0k2.0k(706.0k)(789.0k)789.0k232.0k(231.0k)222.0k961.0k15.0k358.0k452.0k31.0m(6.9m)(14.9m)

Net Income

(25.2m)(12.5m)(20.0m)(17.9m)(26.9m)(24.0m)(1.2m)(37.6m)(1.7m)(10.1m)(24.6m)(31.3m)(12.1m)(26.7m)(16.7m)35.6m(35.8m)(62.9m)(56.9m)7.4m3.5m(11.2m)(976.0k)(1.4m)(40.4m)(4.6m)84.4m(876.0k)26.2m

Ionis Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

46.0m100.1m86.2m85.0m55.3m56.4m85.6m84.6m107.7m296.5m256.4m161.8m94.1m73.2m148.3m119.5m126.6m93.3m112.5m84.3m114.2m133.0m159.2m227.5m805.5m479.9m375.8m272.5m247.9m

Prepaid Expenses

7.0m6.3m7.4m7.6m7.6m7.4m5.7m7.8m8.1m5.8m7.4m9.8m8.6m8.4m13.2m29.9m29.1m17.4m17.3m15.2m25.9m51.5m48.9m62.1m77.0m97.1m98.7m102.1m118.8m

Inventories

8.4m11.1m19.4m

Current Assets

536.9m507.6m437.4m410.7m377.1m347.6m350.4m361.6m431.8m669.1m763.3m722.1m705.8m681.2m835.4m855.5m868.3m763.9m698.0m730.3m962.4m964.4m1.1b1.1b2.1b2.1b2.4b2.4b2.4b

PP&E

36.1m35.5m37.7m88.0m98.0m95.1m94.0m92.6m89.7m88.3m87.3m86.6m86.3m88.1m89.0m89.7m89.2m90.4m90.6m91.0m95.4m99.7m116.6m123.2m127.9m132.0m133.5m135.3m148.7m

Total Assets

606.4m575.9m505.9m529.6m505.8m470.8m472.4m485.7m553.0m788.7m881.9m834.6m817.8m793.8m955.4m976.3m988.0m875.8m811.1m843.6m1.1b1.1b1.3b1.3b2.2b2.2b2.8b2.9b2.9b

Accounts Payable

5.4m3.4m4.7m3.1m6.7m5.3m6.2m5.3m5.4m9.5m8.8m9.9m13.5m15.6m16.5m11.0m19.3m19.5m17.6m15.7m23.2m13.3m23.5m13.8m13.3m13.6m13.3m15.6m13.1m

Short-term debt

5.0m5.1m5.1m4.9m4.2m2.9m5.3m5.2m4.5m4.9m4.6m4.3m4.2m3.7m2.1m1.2m773.0k8.8m8.6m49.0k14.5m14.4m2.1m

Current Liabilities

105.2m100.9m94.4m92.0m83.5m61.7m55.1m51.6m70.3m87.0m103.3m100.8m100.8m107.3m100.3m102.1m122.2m124.5m111.1m106.9m170.6m191.8m177.6m212.6m248.6m260.2m252.5m241.2m231.8m

Long-term debt

5.6m4.3m4.9m5.5m4.7m142.5m145.5m147.1m148.7m152.0m153.7m155.4m508.4m516.5m584.5m601.4m610.1m619.0m637.3m646.7m656.3m

Total Debt

10.6m9.4m10.1m10.4m8.9m2.9m5.3m147.7m150.0m152.0m153.4m156.3m157.9m159.1m2.1m1.2m773.0k8.8m8.6m49.0k508.4m516.5m584.5m601.4m610.1m619.0m651.8m661.1m658.3m

Total Liabilities

344.1m322.1m278.2m317.4m319.0m319.9m318.1m315.4m351.9m387.6m480.5m460.5m450.9m449.0m679.6m675.9m742.6m717.7m699.9m703.9m882.2m875.3m854.9m912.5m1.4b1.4b1.4b1.4b1.4b

Common Stock

99.0k99.0k100.0k100.0k100.0k100.0k100.0k102.0k103.0k114.0k116.0k118.0k118.0k118.0k120.0k120.0k120.0k121.0k121.0k121.0k124.0k124.0k125.0k125.0k137.0k138.0k140.0k140.0k141.0k

Additional Paid-in Capital

991.4m995.1m1.0b1.0b1.0b1.0b1.0b1.1b1.1b1.3b1.3b1.3b1.4b1.4b1.3b1.3b1.3b1.3b1.4b1.4b1.4b1.4b1.5b1.6b2.0b2.0b2.1b2.2b2.2b

Retained Earnings

(730.2m)(742.7m)(776.7m)(794.6m)(821.5m)(865.5m)(866.7m)(904.3m)(908.6m)(918.8m)(943.3m)(998.9m)(1.0b)(1.0b)(1.0b)(987.7m)(1.0b)(1.2b)(1.2b)(1.2b)(1.2b)(1.2b)(1.2b)(1.2b)(1.3b)(1.3b)(882.8m)(883.7m)(857.6m)

Total Equity

262.2m253.7m227.7m212.2m186.8m150.9m154.3m170.3m201.1m401.1m401.4m374.1m366.9m344.8m275.9m300.3m245.4m158.2m111.2m139.6m201.8m215.6m397.7m387.1m817.4m840.1m1.4b1.5b1.5b

Financial Leverage

2.3 x2.3 x2.2 x2.5 x2.7 x3.1 x3.1 x2.9 x2.7 x2 x2.2 x2.2 x2.2 x2.3 x3.5 x3.3 x4 x5.5 x7.3 x6 x5.4 x5.1 x3.1 x3.4 x2.7 x2.7 x2 x2 x1.9 x

Ionis Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(34.8m)(47.3m)(20.0m)(37.9m)(64.8m)(24.0m)(25.2m)(62.8m)(1.7m)(11.8m)(31.3m)(43.4m)(70.0m)(16.7m)18.9m(16.8m)(62.9m)(119.8m)(112.4m)3.5m(7.7m)(12.6m)(10.8m)(67.4m)(87.7m)90.9m80.9m99.3m

Depreciation and Amortization

1.6m3.1m4.8m1.6m3.4m5.2m1.8m3.7m5.6m2.0m4.0m6.1m2.4m4.9m7.7m3.5m7.2m10.5m

Inventories

496.0k257.0k948.0k(549.0k)(492.0k)(293.0k)379.0k(769.0k)(2.4m)688.0k985.0k(962.0k)922.0k915.0k1.6m(2.5m)(5.7m)(6.6m)

Accounts Payable

(2.6m)2.0m1.4m(2.7m)(8.2m)862.0k(11.4m)(12.4m)(15.2m)472.0k(10.0m)(1.7m)(13.1m)(14.2m)(13.6m)(17.2m)(16.1m)(18.8m)

Cash From Operating Activities

(16.7m)(38.1m)(39.8m)(66.0m)(90.5m)(6.7m)(9.3m)(34.2m)(10.6m)12.2m78.0m(32.3m)(66.3m)(64.4m)(42.8m)22.4m58.6m(75.8m)(109.6m)(86.1m)122.7m125.0m153.7m13.2m513.4m487.4m107.7m80.6m67.8m

Purchases of PP&E

(11.9m)(12.7m)(2.6m)(6.0m)(7.7m)(113.0k)(864.0k)(1.0m)(222.0k)(591.0k)(1.1m)(1.4m)(3.1m)(4.0m)(878.0k)(3.9m)(5.3m)(628.0k)(3.3m)(4.3m)(3.2m)(9.5m)(26.5m)(2.3m)(9.0m)(12.2m)(3.2m)(7.2m)(23.1m)

Cash From Investing Activities

(45.0m)30.9m56.7m81.4m76.9m(522.0k)23.6m13.0m(15.3m)(47.1m)(170.5m)24.8m(7.6m)(32.1m)36.7m(58.7m)(88.0m)39.4m92.9m35.8m(168.7m)(154.0m)(304.1m)79.5m(295.7m)(603.4m)(70.2m)(180.9m)(179.5m)

Long-term Borrowings

(1.9m)(3.1m)(1.4m)(2.9m)(4.4m)(2.5m)(4.8m)(7.6m)(2.8m)(5.6m)(8.3m)(2.7m)(5.4m)(8.0m)(2.6m)(5.2m)(7.3m)(1.9m)(3.7m)(5.4m)(1.6m)(3.3m)(3.6m)(12.5m)

Cash From Financing Activities

2.4m2.0m(728.0k)(369.0k)(1.3m)(1.9m)5.9m40.3m9.1m207.0m224.4m9.3m8.0m9.7m11.5m12.8m13.0m879.0k403.0k5.8m75.5m77.3m224.8m5.2m458.1m466.2m59.5m94.0m80.8m

Net Change in Cash

(59.2m)(5.1m)16.1m15.0m(14.8m)(9.1m)20.2m19.1m(16.8m)172.1m131.9m1.8m(65.9m)(86.8m)5.4m(23.5m)(16.4m)(35.5m)(16.3m)(44.5m)29.5m48.3m74.5m97.9m675.9m350.3m97.0m(6.3m)(30.9m)

Interest Paid

2.4m4.7m2.3m2.4m4.6m2.2m2.3m5.6m113.0k3.0m3.1m83.0k2.9m3.0m37.0k3.4m4.2m31.0k3.4m4.3m106.0k3.6m4.0m644.0k4.8m5.4m667.0k4.8m5.5m

Income Taxes Paid

7.7m7.7m2.0k2.0k2.0k2.0k2.0k2.0k9.0m

Ionis Pharmaceuticals Ratios

USDY, 2019

EV/EBIT

3.5 k x

EV/CFO

128.7 x

Financial Leverage

1.9 x

Ionis Pharmaceuticals Employee Rating

3.239 votes
Culture & Values
3.0
Work/Life Balance
2.9
Senior Management
2.8
Salary & Benefits
3.5
Career Opportunities
2.9
Source